Rapamycin for inclusion body myositis: targeting non-inflammatory mechanisms

Rheumatology (Oxford). 2019 Mar 1;58(3):375-376. doi: 10.1093/rheumatology/key043.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Myositis, Inclusion Body / drug therapy*
  • Sirolimus / therapeutic use*

Substances

  • Immunosuppressive Agents
  • Sirolimus